Axsome Therapeutics, Inc. (AXSM)
NASDAQ · Healthcare
Axsome Therapeutics, Inc. Operating Income 2022–2025
Axsome Therapeutics, Inc. annual/quarterly operating income history and growth rate from 2022 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Axsome Therapeutics, Inc. operating income for the quarter ending March 31, 2026 was -63.4 M, a 11.19% increase year-over-year.
- Axsome Therapeutics, Inc. operating income for the twelve months ending March 31, 2026 was -203.2 M, a 24.77% decrease year-over-year.
- Axsome Therapeutics, Inc. annual operating income for 2025 was -166.8 M, a 40.56% decrease from 2024.
- Axsome Therapeutics, Inc. annual operating income for 2024 was -280.6 M, a 21.02% increase from 2023.
- Axsome Therapeutics, Inc. annual operating income for 2023 was -231.8 M, a 28.94% increase from 2022.
- Axsome Therapeutics, Inc. annual operating income for 2022 was -179.8 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Axsome Therapeutics, Inc. Operating Income — FAQ
Axsome Therapeutics, Inc. (AXSM) operating income over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
What is Axsome Therapeutics, Inc.'s operating income?
Axsome Therapeutics, Inc. (AXSM) reported operating income of -$167M for fiscal 2025.
Where can I see AXSM's operating income history?
The chart and table above show Axsome Therapeutics, Inc.'s operating income by year and by quarter, including the growth rate.